According to the Shanghai Pharmaceutical announcement, Changzhou Pharmaceutical Co., Ltd., a subsidiary of the company, received a “Drug Registration Certificate” for rucotinib phosphate tablets issued by the State Drug Administration, and the drug was approved for production. This drug is a class of 4 chemicals. The specifications include 5 mg, 15 mg, and 20 mg. It is suitable for indications related to myelofibrosis and graft-versus-host disease. As of the announcement date, the company has invested about 24.81 million yuan in research and development expenses for this drug. In 2025, hospitals in mainland China purchased the drug for 717 million yuan. The approval of the drug is conducive to expanding market share and enhancing competitiveness, but there is uncertainty about its sales falling short of expectations.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.